Orris

Discuss the role of targeted therapy in management of head and neck cancers in detail for 20 marks with diagram and flow charts from Scott Brown, Cummings, stell and marans, Zakir Hussain, dhingra, hazarika and related articles with recent advances according to rguhs university

Reading File
Finding Sources
Searching PubMed

"head and neck cancer" AND "targeted therapy" AND "cetuximab"

Searching the Web

targeted therapy head neck cancer RGUHS 2024 cetuximab immunotherapy EGFR

Finding Sources
Searching PubMed

"head and neck squamous cell carcinoma" AND "immunotherapy" AND "pembrolizumab"

Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
This is a comprehensive, exam-ready 20-mark answer for RGUHS. Here is a structured summary of what was covered:

Answer Structure Overview

The answer covers 10 major sections with ASCII diagrams and flowcharts:

1. Introduction & Rationale

  • EGFR overexpressed in 90% of HNSCC - the molecular basis for targeted therapy
  • Sources: Scott-Brown's + Cummings

2. EGFR Signaling Pathway Diagram

  • Full cascade: EGF → EGFR → RAS/MAPK / PI3K/AKT → Proliferation/Survival
  • Downstream effects including angiogenesis (VEGF) and anti-apoptosis

3. Classification of Targeted Agents

Four categories: Anti-EGFR mAbs, TKIs, Immune Checkpoint Inhibitors, Anti-angiogenics

4. Cetuximab - Cornerstone Drug

  • Mechanism, dosing, Bonner Trial (OS 49 vs 29.3 months), EXTREME Trial (OS 10.1 vs 7.4 months)
  • Sources: KJ Lee's, Cummings, Scott-Brown's

5. Integrated Management Flowchart

  • From diagnosis → staging → cisplatin fitness → PD-L1 testing → treatment selection

6. Immune Checkpoint Inhibitors

  • CheckMate-141 (Nivolumab - OS 7.5 vs 5.1 months), KEYNOTE-048 (Pembrolizumab now preferred 1st-line for PD-L1 CPS ≥1)

7. TKIs & Anti-angiogenics

  • Gefitinib, Erlotinib, Afatinib (LUX-HN1), Bevacizumab

8. Toxicity Profile

  • Cetuximab: acneiform rash (paradoxically = better response), infusion reactions
  • irAEs with ICIs: 10-system table from KJ Lee's

9. Biomarkers & HPV

  • RTOG 1016: Cetuximab inferior to cisplatin in HPV+ oropharynx (critical exam point)

10. Recent Advances (2024-2026)

  • Nimotuzumab, bispecific antibodies, ADCs, neoadjuvant ICI, KEYNOTE-412, tarloxotinib
Key exam points boxed at the end with 8 high-yield facts for RGUHS viva.
This is a shared conversation. Sign in to Orris to start your own chat.